Prevalence of serum bactericidal antibody to serogroup C Neisseria meningitidis in England a decade after vaccine introduction.

Immunisation Department, Health Protection Agency, Colindale, London, United Kingdom.
Clinical and vaccine Immunology: CVI (Impact Factor: 2.37). 05/2012; 19(8):1126-30. DOI: 10.1128/CVI.05655-11
Source: PubMed

ABSTRACT Serogroup C meningococcal disease incidence and carriage declined rapidly in the United Kingdom after infant serogroup C conjugate vaccination was introduced in 1999, with catch-up vaccination for children under 18 years. Antibody levels and effectiveness waned quickly in children vaccinated at 2, 3, and 4 months of age. Therefore, in 2006, the current revised schedule of doses at 3, 4, and 12 months was introduced. This study assessed age-specific protection in 2009 compared with data from historical prevaccination and early postvaccination studies. Rabbit complement serum bactericidal antibody (SBA) was measured in anonymously banked serum samples collected in England in 2009 (n = 1,174), taking titers of ≥ 8 as protective. Age-stratified proportions of SBA titers that were ≥ 8 and geometric mean titers were compared. SBA titers varied markedly by birth cohort and time since vaccination. Overall, 35% of samples (95% confidence interval [CI], 33 to 38%) had titers that were ≥ 8. Only in cohorts eligible for catch-up vaccination did the majority of individuals have protective antibody levels. Antibody levels were higher in children eligible for vaccination at primary and secondary school ages, compared to those eligible below the age of 5 years. In those eligible for completed vaccination under the current schedule, protective levels were very modest and there was no evidence of superiority to cohorts that were eligible for the previous schedule. This supports a need for older childhood or adolescent booster vaccination in those previously eligible for vaccination during the infant, toddler, or preschool periods, to maintain direct protection and potentially enhance population immunity.

Download full-text


Available from: Caroline L Trotter, Jul 05, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The epidemiology of invasive meningococcal disease continues to change rapidly, even in the three years since the first Meningococcal Exchange Meeting in 2008. Control of disease caused by serogroup C has been achieved in countries that have implemented meningococcal C or quadrivalent meningococcal ACWY conjugate vaccines. Initiation of mass immunization programs with meningococcal A conjugate vaccines across the meningitis belt of Africa may lead to the interruption of cyclical meningococcal epidemics. A meningococcal B vaccination program in New Zealand has led to a decreased incidence of high rates of endemic serogroup B disease. Increases in serogroup Y disease have been observed in certain Nordic countries which, if they persist, may require consideration of use of a multiple serogroup vaccine. The imminent availability of recombinant broadly protective serogroup B vaccines may provide the tools for further control of invasive meningococcal disease in areas where serogroup B disease predominates. Continued surveillance of meningococcal disease is essential; ongoing global efforts to improve the completeness of reporting are required.
    Vaccine 12/2011; 30 Suppl 2:B26-36. DOI:10.1016/j.vaccine.2011.12.032 · 3.49 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: From 1999, in the United Kingdom, meningococcal C conjugate (MCC) vaccines from 3 manufacturers were introduced to the infant immunization schedule at 2, 3 and 4 months of age. In 2006, the schedule was refined to a 2-dose primary schedule at 3 and 4 months of age, with a combined MCC/Haemophilus influenzae type b (MCC/Hib-TT) booster at 12 months of age. Recent data have demonstrated that 2 of the 3 MCC vaccines showed potential for use as a single priming dose in infancy. A randomized trial was undertaken with 2 MCC vaccines; one using tetanus toxoid carrier protein (MCC-TT) and one using CRM197 carrier protein (MCC-CRM197). Infants were immunized with MCC at 3 months of age followed by an MCC/Hib-TT booster at 12 months of age. The serum bactericidal antibody geometric mean titers 1 month after a single dose of MCC-TT or MCC-CRM 197 were 223.3 (95% confidence interval [CI]: 162.9-306.1) and 95.8 (95% CI: 66.4-138.2) with 100% and 95.5% of infants having serum bactericidal antibody titers ≥ 8, respectively. Before boosting, antibody titers had declined, and 1 month after the MCC/Hib-TT booster, serum bactericidal antibody geometric mean titers rose to 2251.0 (95% CI: 1535.3-3300.3) and 355.9 (95% CI: 235.4-538.1) for children primed with MCC-TT and MCC-CRM 197, respectively. In conclusion, a single priming dose of either MCC-TT or MCC-CRM197 administered at 3 months of age can be used together with the Hib/MCC-TT booster in the second year of life.
    The Pediatric Infectious Disease Journal 02/2012; 31(6):616-22. DOI:10.1097/INF.0b013e31824f34e6 · 3.14 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: The global disease burden of serious bacterial infections is caused mainly by Haemophilus influenzae type b (Hib), Streptococcus pneumoniae and Neisseria meningitidis. Death or disability may be the potential aftermath of invasive infections with these pathogens. Active immunisation is the only rational approach in preventing such infections. Areas covered: This review discusses the immunology of vaccination and describes the immunogenicity, safety and impact of glycoconjugate vaccines that have been developed against Hib, the most prevalent serotypes of S. pneumoniae and N. meningitidis serogroups A, C, W-135 and Y in all ages. The immune response to the plain polysaccharide vaccines that target the same pathogens is compared to that induced by the respective glycoconjugate vaccine formulations. Expert opinion: Continued surveillance is necessary to recognise any epidemiological changes influenced by the impact of glycoconjugate vaccines and is crucial in guiding future vaccination strategies. Although, in general, the immunogenicity of glycoconjugate vaccines results in robust immune responses in all ages, subsequent booster doses may be necessary to sustain protection. Challenges in addressing inequities in vaccine availability between industrialised and developing countries are still there. The limitations of plain polysaccharide vaccines make immunisation with glycoconjugates a more sustainable long term option.
    Expert opinion on biological therapy 09/2012; DOI:10.1517/14712598.2012.725718 · 3.65 Impact Factor